There are many options for the prophylaxis of chemotherapy-induced nausea and vomiting. Among them are cannabinoids, diphenhydramine, palonosetron, and metoclopramide. This article will discuss the different options and their benefits and disadvantages. It will also provide you with some useful tips on reducing the frequency of nausea and vomiting.


The use of cannabinoids in cancer therapy is a promising way to combat nausea and vomiting related to chemotherapy. This also explains why more users are looking for fast cannabis seeds and grow their own weeds at home.

However, this treatment option has some drawbacks, including the possibility of side effects. To address this problem, newer drugs are being developed, such as cannabidiol and dronabinol, which act on the brain and are used to alleviate nausea and vomiting related to cancer treatment.


This medication can help patients cope with chemotherapy-induced nausea and vomiting. It can help with nausea and vomiting associated with various chemotherapy drugs. In a study published in N Engl J Med, the drug metoclopramide was found to be as effective as dexamethasone. The length of the delay depends on the emetogenicity of the chemotherapy drug.


The newest guidelines from the American Society for Clinical Oncology describe a new class of antiemetic drugs for chemotherapy-induced nausea and vomiting. They also include a cost sheet and tiered recommendations based on emetic risk. These guidelines also provide guidance on the use of medical marijuana. This article is a brief summary of new guidelines for the management of chemotherapy-induced nausea and vomiting.


There is increasing evidence that palonosetron is an effective treatment for the prevention and reduction of Chemotherapy-induced nausea (CINV). The drug has improved symptomatic relief over first-generation 5-HT3 RAs. These compounds are highly selective for 5-HT3 receptors, which make them superior treatments for CINV. In phase III trials, palonosetron showed superior efficacy compared to traditional 5-HT3 RAs for both acute and delayed CINV prevention. Also, the drug’s long-acting and convenient dosing schedules simplify the patient’s regimen.

High-dose metoclopramide

More than 80% of patients undergoing chemotherapy will experience chemotherapy-induced nausea and vomiting (CINV), which can disrupt the treatment regimen, reduce oral intake of fluids, and even compromise the quality of life of the patient. The primary objective of antiemetic therapy is to prevent or reduce the risk of vomiting and nausea during chemotherapy. Chemotherapy-induced nausea and vomiting can lead to serious problems, including dehydration, malnutrition, esophageal tears, fractures, wound dehiscence, and loss of mental status. As the cost of medical treatment increases, the management of CINV becomes more critical.

High-dose diphenhydramine

Diphenhydramine is a common symptom reliever. However, it is not an effective cure for colds, and it does not speed up the recovery process. It is also not recommended for use by children because it may cause sleepiness. Diphenhydramine belongs to the class of antihistamines, which block the action of histamine, a chemical that causes allergic reactions.

Low-dose metoclopramide

Studies have shown that low-dose metoclopramide can reduce nausea and vomiting associated with cancer therapy. One study compared granisetron with ondansetron in patients with advanced breast cancer. However, there is no clear evidence that metoclopramide is as effective as ondansetron in treating chemotherapy-induced nausea and vomiting.

Related Posts